Palatin Technologies (PTN) Enterprise Value (2010 - 2026)
Palatin Technologies' (PTN) quarterly Enterprise Value came in at $58.0 million in Q1 2026, up 354.45% on a YoY basis from $12.8 million in Q1 2025, and up 135.88% quarter-over-quarter from $24.6 million in Q4 2025.
Analysis
Palatin Technologies (PTN) Enterprise Value (2010 - 2026) Analysis & Trends
Palatin Technologies (PTN) has reported Enterprise Value for 17 consecutive years, with $58.0 million the latest figure, recorded in Q1 2026.
- For the quarter ending Q1 2026, Enterprise Value rose 354.45% year-over-year to $58.0 million; the trailing twelve-month figure through Mar 2026 stood at $58.0 million (up 354.45% YoY), and the FY2025 full-year result was $100.3 million, down 92.95% from the prior year.
- Enterprise Value climbed to $58.0 million in Q1 2026 per PTN's latest filing, from $24.6 million in the prior quarter.
- Across five years, Enterprise Value topped out at $133.2 billion in Q1 2022 and bottomed at $1.1 million in Q2 2025.
- Historically, Enterprise Value has averaged $20.8 billion across 5 years, with a median of $1.3 billion in 2024.
- The sharpest annual moves came in 2025 and 2026: Enterprise Value tumbled 99.92% in 2025, then surged 354.45% in 2026.
- Over 5 years, Enterprise Value stood at $29.6 billion in 2022, then sank by 90.43% to $2.8 billion in 2023, then tumbled by 54.24% to $1.3 billion in 2024, then slumped by 98.11% to $24.6 million in 2025, then surged by 135.88% to $58.0 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered $58.0 million, $24.6 million, and $6.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Palatin Technologies | 46.98 Mn | 46.98 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 57.99 Mn |
| Dec 31, 2025 | 24.58 Mn |
| Sep 30, 2025 | 6.44 Mn |
| Jun 30, 2025 | 1.12 Mn |
| Mar 31, 2025 | 12.76 Mn |
| Dec 31, 2024 | 1.30 Bn |
| Sep 30, 2024 | 867.51 Mn |
| Jun 30, 2024 | 1.42 Bn |
| Mar 31, 2024 | 1.33 Bn |
| Dec 31, 2023 | 2.84 Bn |
| Sep 30, 2023 | 896.45 Mn |
| Jun 30, 2023 | 1.21 Bn |
| Mar 31, 2023 | 31.85 Bn |
| Dec 31, 2022 | 29.65 Bn |
| Sep 30, 2022 | 68.58 Bn |
| Jun 30, 2022 | 81.09 Bn |
| Mar 31, 2022 | 133.23 Bn |
| Dec 31, 2021 | 147.66 Bn |
| Sep 30, 2021 | 127.16 Bn |
| Jun 30, 2021 | 175.35 Bn |